Lyrica Generics Were Likely Delayed By A Pfizer Labeling Supplement
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
You may also be interested in...
Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes
A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.
Lyrica Generics Launch, But Pfizer Has Been Bracing For The Hit
The first generic versions of Pfizer's blockbuster pain medicine pregabalin have launched in the US. Pfizer has guided investors the company will return to growth in 2020 after cycling through the loss.
Lyrica Rivals Are Rolled Out In The US
Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.